beta-lapachone has been researched along with Diabetic Cardiomyopathies in 1 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, PY | 1 |
| Lai, SY | 1 |
| Su, YT | 1 |
| Yang, KC | 1 |
| Chau, YP | 1 |
| Don, MJ | 1 |
| Lu, KH | 1 |
| Shy, HT | 1 |
| Lai, SM | 1 |
| Kung, HN | 1 |
1 other study available for beta-lapachone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
β-Lapachone, an NQO1 activator, alleviates diabetic cardiomyopathy by regulating antioxidant ability and mitochondrial function.
Topics: Animals; Antioxidants; Diabetes Mellitus; Diabetic Cardiomyopathies; Mice; Mice, Inbred C57BL; Mitoc | 2022 |